63 related articles for article (PubMed ID: 35362337)
1. Projecting long-term clinical outcomes with larotrectinib compared with immune checkpoint inhibitors in metastatic nonsmall cell lung cancer and differentiated thyroid cancer.
Suh K; Kang A; Ko G; Williamson T; Liao N; Sullivan SD
J Manag Care Spec Pharm; 2024 Jun; 30(6):581-587. PubMed ID: 38824630
[TBL] [Abstract][Full Text] [Related]
2. Survival Outcomes of Patients With Tropomyosin Receptor Kinase Fusion-Positive Cancer Receiving Larotrectinib Versus Standard of Care: A Matching-Adjusted Indirect Comparison Using Real-World Data.
Bokemeyer C; Paracha N; Lassen U; Italiano A; Sullivan SD; Marian M; Brega N; Garcia-Foncillas J
JCO Precis Oncol; 2023 Jan; 7():e2200436. PubMed ID: 36689698
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic benefit of larotrectinib over the historical standard of care in patients with locally advanced or metastatic infantile fibrosarcoma (EPI VITRAKVI study).
Orbach D; Carton M; Khadir SK; Feuilly M; Kurtinecz M; Phil D; Vokuhl C; Koscielniak E; Pierron G; Lemelle L; Sparber-Sauer M
ESMO Open; 2024 May; 9(5):103006. PubMed ID: 38657345
[TBL] [Abstract][Full Text] [Related]
4. Larotrectinib versus historical standard of care in patients with infantile fibrosarcoma: protocol of EPI-VITRAKVI.
Carton M; Del Castillo JP; Colin JB; Kurtinecz M; Feuilly M; Pierron G; Arvis P; Khadir SK; Sparber-Sauer M; Orbach D
Future Oncol; 2023 Aug; 19(24):1645-1653. PubMed ID: 37133249
[TBL] [Abstract][Full Text] [Related]
5. Tackling Challenges in Assessing the Economic Value of Tumor-Agnostic Therapies: A Cost-Effectiveness Analysis of Pembrolizumab as a Case Study.
Chen Y; Martin P; Inoue LYT; Basu A; Carlson JJ
Value Health; 2024 Mar; ():. PubMed ID: 38548177
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Olaratumab in Combination with Doxorubicin for Patients with Soft Tissue Sarcoma in the United States.
Zuluaga-Sanchez S; Hess LM; Wolowacz SE; D'yachkova Y; Hawe E; Vickers AD; Kaye JA; Bertwistle D
Sarcoma; 2018; 2018():6703963. PubMed ID: 29785170
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection.
Bullement A; Willis A; Amin A; Schlichting M; Hatswell AJ; Bharmal M
BMC Med Res Methodol; 2020 May; 20(1):103. PubMed ID: 32375680
[TBL] [Abstract][Full Text] [Related]
8. Larotrectinib in a NTRK-rearranged soft tissue sarcoma in the neoadjuvant setting: A case report.
Percy C; Schubert T; Galant C; Kirchgesner T; Mazzeo F
Clin Case Rep; 2021 Mar; 9(3):1694-1698. PubMed ID: 33768917
[TBL] [Abstract][Full Text] [Related]
9. Clinical benefit of anti-PD-(L)1 immunotherapies in advanced cancer in France: a population-based estimate from 2014 to 2021.
Grumberg V; Cotté FE; Giroux-Leprieur E; Gaudin AF; Lebbé C; Borget I
ESMO Open; 2024 Feb; 9(2):102240. PubMed ID: 38335904
[TBL] [Abstract][Full Text] [Related]
10. Comparing current and emerging practice models for the extrapolation of survival data: a simulation study and case-study.
Kearns B; Stevenson MD; Triantafyllopoulos K; Manca A
BMC Med Res Methodol; 2021 Nov; 21(1):263. PubMed ID: 34837957
[TBL] [Abstract][Full Text] [Related]
11. Assessing the Performance of Alternative Methods for Estimating Long-Term Survival Benefit of Immuno-oncology Therapies.
Monnickendam G
Value Health; 2024 Feb; ():. PubMed ID: 38428815
[TBL] [Abstract][Full Text] [Related]
12. Validation of overall survival extrapolations made by TLV in the assessment of cost-effectiveness of oncology drugs in Sweden - A pilot study comparing extrapolated and observed life-years gained.
Björnerstedt J; Almqvist H; Lundin D; Zethraeus N
J Med Econ; 2024; 27(1):193-200. PubMed ID: 38225911
[TBL] [Abstract][Full Text] [Related]
13. Larotrectinib Demonstrates CNS Efficacy in TRK Fusion-Positive Solid Tumors.
Rosen EY; Schram AM; Young RJ; Schreyer MW; Hechtman JF; Shu CA; Ku NC; Hyman DM; Drilon A
JCO Precis Oncol; 2019; 3():. PubMed ID: 32914009
[No Abstract] [Full Text] [Related]
14. Marked effect of larotrectinib on primary cutaneous secretory carcinoma: A case report.
Hayakawa K; Irisawa R; Umefune R; Mae K; Shimada Y; Takahashi R; Nagao T; Harada K
J Dermatol; 2024 Apr; ():. PubMed ID: 38605458
[No Abstract] [Full Text] [Related]
15. Weibull parametric model for survival analysis in women with endometrial cancer using clinical and T2-weighted MRI radiomic features.
Li X; Marcus D; Russell J; Aboagye EO; Ellis LB; Sheeka A; Park WE; Bharwani N; Ghaem-Maghami S; Rockall AG
BMC Med Res Methodol; 2024 May; 24(1):107. PubMed ID: 38724889
[TBL] [Abstract][Full Text] [Related]
16. The potential long-term comparative effectiveness of larotrectinib vs standard of care for treatment of metastatic TRK fusion thyroid cancer, colorectal cancer, and soft tissue sarcoma.
Suh K; Carlson JJ; Xia F; Williamson T; Sullivan SD
J Manag Care Spec Pharm; 2022 Jun; 28(6):622-630. PubMed ID: 35362337
[No Abstract] [Full Text] [Related]
17. The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer.
Roth JA; Carlson JJ; Xia F; Williamson T; Sullivan SD
J Manag Care Spec Pharm; 2020 Aug; 26(8):981-986. PubMed ID: 32329651
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of larotrectinib versus entrectinib for the treatment of metastatic
Suh K; Carlson JJ; Xia F; Williamson T; Sullivan SD
J Comp Eff Res; 2022 Oct; 11(14):1011-1019. PubMed ID: 35993247
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
